A Phase 1/2 Study of Brentuximab Vedotin (SGN35) in Combination With Gemcitabine for Pediatric and Young Adult Patients With Relapsed or Refractory Hodgkin Lymphoma
Latest Information Update: 12 May 2022
At a glance
- Drugs Brentuximab vedotin (Primary) ; Gemcitabine (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 26 Apr 2022 Results reporting durable remission for four pediatric patients with high-risk relapsed classical Hodgkin lymphoma treated with brentuximab vedotin plus gemcitabine but without autologous stem cell transplantation published in the Pediatric Blood and Cancer
- 01 Oct 2019 Results published in the ClinicalTrials.gov Trial Registry.
- 16 Aug 2018 Results (46) published in the Lancet Oncology.